Here's Why Shares in Agios Pharmaceuticals Popped Today
Key Points
The new indication is relatively rare in the U.S., but pricing is substantial, and the need for the treatment is significant.
The positive update turns the company's fortunes around after a disappointing update earlier in the year.
- 10 stocks we like better than Agios Pharmaceuticals ›
Shares in Agios Pharmaceuticals (NASDAQ: AGIO) soared by more than 18% as of 11 a.m. today. The move follows the company's receipt of approval from the Food and Drug Administration (FDA) for AQVESME (mitapivat) for the treatment of anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia. Additionally, management held a positive conference call to discuss the approval and outlined its marketing and pricing plans.
FDA approval
Thalassemia is an inherited blood disorder that leads to the body producing insufficient hemoglobin protein, causing excessive tiredness and weakness and ultimately increased morbidity. Mitapivat targets the mechanism within the red blood cells themselves, enabling stronger and longer-lasting red blood cells. As such, it is expected to reduce fatigue and the need for transfusions for sufferers.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
The marketing plan
During the conference call, the pharmaceutical company's management noted it had an "addressable launch population" of 4,000 patients (Thalassemia is a relatively rare disease in the U.S., but more prevalent worldwide) and a price of $425,000 a year in the U.S.
Combined with its approval in other indications (mitapivat is already FDA approved for adults with Pyruvate Kinase Deficiency (PKD) and management believes it has the "potential to deliver $1bn global peak-year-sales across PKD and thalassemia indications."That could increase if migratory trends toward the U.S. bring more potential thalassemia patients and their descendants into the U.S. market.
Image source: Getty Images.
It's a positive result after an earlier disappointment with mitapivat in a sickle cell disease trial, and the company is on track to rapidly expand sales following this approval.
Should you buy stock in Agios Pharmaceuticals right now?
Before you buy stock in Agios Pharmaceuticals, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Agios Pharmaceuticals wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $504,239!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,159,896!*
Now, it’s worth noting Stock Advisor’s total average return is 985% — a market-crushing outperformance compared to 195% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of December 24, 2025.
Lee Samaha has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
